Fig. 1 · Structure

Documents & Downloads

Gimeracil

Cat. No. A11682 CAS 103766-25-2
Gimeracil, an inhibitor of dihydropyrimidine dehydrogenase, inhibits the early step in homologous recombination.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Gimeracil Research Summary

This section summarizes 2 in vitro studies and 2 in vivo studies of Gimeracil from 3 published references. In vitro models include MDA‐MB‐231 LLM cells; SAS.

Gimeracil In Vitro Studies

Gimeracil treatment did not change mesenchymal and epithelial marker expression in MDA‐MB‐231 LLM cells. In the SAS cell study, CDHP was reported not to inhibit the growth of SAS or HSC2 cells. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Mesenchymal and Epithelial Marker Expression in LLM Cells

Cell-based study · MDA‐MB‐231 LLM cells [1]

MDA‐MB‐231 LLM cells were treated with Gimeracil. Treatment did not change the expression of mesenchymal and epithelial markers.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
expression of mesenchymal and epithelial markersReported result 5‐Chloro‐2,4‐dihydroxypyridine treatment does not change the expression of mesenchymal and epithelial markers[1]

Literature-Reported Treatment Conditions

Exposure duration
3 days
Method
treated with CDHP
Vehicle
dimethyl sulfoxide (DMSO)
Reported limits
Not stated in the sentences used: dose, control.
Methods and source locations

Compound reported in the paper: Gimeracil; Compound label in the paper: 5-Chloro-2 4-dihydroxypyridine

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > Cell culture (S7, S8); Materials and Methods > Immunocytochemistry (S17, S18); Figure 2 legend (S40, S41, S42)

expression of mesenchymal and epithelial markers: expression of mesenchymal and epithelial markers — Figure 2 legend (S40)

Cell Growth Following Treatment in SAS Cells

Cell-based study · SAS [2]

SAS cells were treated with Gimeracil and compared with an untreated control. The reported result was that CDHP did not inhibit the growth of SAS or HSC2 cells.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
cell growth inhibitionReported result CDHP did not inhibit the growth of SAS or HSC2 cells[2]

Literature-Reported Treatment Conditions

Treatment concentration
5, 10, 50 and 100 µg/ml
Exposure duration
24, 48 or 72 h
Reported limits
Not stated in the sentences used: route, vehicle.
Methods and source locations

Compound reported in the paper: Gimeracil; Compound label in the paper: 5-Chloro-2 4-dihydroxypyridine

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Untitled > Cell lines and cell culture (S1); Materials and methods > Untitled > In vitro cell growth assay (S4, S5); Results > Untitled > Effects of CDHP and CDDP on cell growth inhibition of OSCC cell lines in vitro (S59, S60); Figure 1. legend (S75, S76, S81)

cell growth inhibition: cell growth inhibition; comparator: untreated control — Results > Untitled > Effects of CDHP and CDDP on cell growth inhibition of OSCC cell lines in vitro (S60); Figure 1. legend (S75, S76)

Gimeracil In Vivo Studies

In athymic nude mice bearing HSC2 tumor xenografts, oral Gimeracil treatment produced no observed growth inhibition compared with HPMC treatment. In C57BL/6J mice receiving CDAHFD, liver hydroxyproline measurements decreased with dietary Gimeracil compared with CDAHFD without gimeracil. [2,3]

Tumor Growth in Athymic Nude Mice

Animal study · Cg-Foxnlnu/CrlCrlj athymic nude mice; HSC2 tumor xenografts [2]

Athymic nude mice bearing HSC2 tumor xenografts received Gimeracil orally via a gastric tube. Growth inhibition was not observed in CDHP-treated tumors compared with HPMC-treated tumors.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
tumor volumesReported result Growth inhibition was not observed in CDHP-treated tumors compared with that in HPMC-treated tumors[2]

Conditions shared by the study groups

Route
orally via a gastric tube
Treatment course
for 2 weeks (7 times/week)
Vehicle
sterile 0.5% sodium hydroxypropylmethylcellulose
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Gimeracil 2.0 mg/kg0.5% HPMC for 2 weeks (7 times/week) and saline (200 µl) intraperitoneally for 2 weeks (once/week)Growth inhibition was not observed in CDHP-treated tumors compared with that in HPMC-treated tumors[2]
Gimeracil 2.0 mg/kg
Model: Cg-Foxnlnu/CrlCrlj athymic nude mice; HSC2 tumor xenografts
Methods and source locations

Compound reported in the paper: Gimeracil; Compound label in the paper: 5-Chloro-2 4-dihydroxypyridine

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Untitled > Nude mice and tumor inoculations (S25, S28); Materials and methods > Untitled > Reagents and in vivo treatment protocol (S38, S39, S40, S43); Results > Untitled > Effects of CDHP and CDDP on tumor growth inhibition in vivo (S65, S67); Figure 4. legend (S97)

tumor volumes: tumor volumes; comparator: 0.5% HPMC for 2 weeks (7 times/week) and saline (200 µl) intraperitoneally for 2 weeks (once/week) — Materials and methods > Untitled > Reagents and in vivo treatment protocol (S43); Results > Untitled > Effects of CDHP and CDDP on tumor growth inhibition in vivo (S67)

Gimeracil 2.0 mg/kg · Materials and methods > Untitled > Reagents and in vivo treatment protocol (S40); Results > Untitled > Effects of CDHP and CDDP on tumor growth inhibition in vivo (S67)

Liver Hydroxyproline Measurements in Diet-Treated Mice

Animal study · C57BL/6J mice; N = 8 to 12 per group. [3]

C57BL/6J mice received CDAHFD with or without Gimeracil. Liver hydroxyproline measurements decreased in the gimeracil-treated group compared with the control group receiving CDAHFD without gimeracil.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Liver hydroxyproline measurementsliver hydroxyproline ~25% decrease[3]

Conditions shared by the study groups

Route
added in the CDAHFD diet
Treatment course
12 wk of treatment
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Gimeracil 260 mg gimeracil per kg diet, estimated to result in a dosing of 25 mg/kg/dwithout it (Ctrl)an ~25% (P = 0.02) decrease in the gimeracil-treated group as compared to the Ctrl group[3]
Gimeracil 260 mg gimeracil per kg diet, estimated to result in a dosing of 25 mg/kg/d
Model: C57BL/6J mice; N = 8 to 12 per group.
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Gimeracil

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Inhibition of Pyrimidine Catabolism by Gimeracil Protects against Liver Fibrosis. (S39, S42); Materials and Methods > Mouse Models. (S71, S74); Fig. 5. legend (S143, S144, S146)

Liver hydroxyproline measurements: Liver hydroxyproline measurements; comparator: without it (Ctrl) — Results > Inhibition of Pyrimidine Catabolism by Gimeracil Protects against Liver Fibrosis. (S42); Fig. 5. legend (S144)

Gimeracil 260 mg gimeracil per kg diet, estimated to result in a dosing of 25 mg/kg/d · Results > Inhibition of Pyrimidine Catabolism by Gimeracil Protects against Liver Fibrosis. (S39, S42); Materials and Methods > Mouse Models. (S74)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 103766-25-2
Formula C5H4ClNO2
Molecular Weight 145.54
SMILES
C1=C(C(=CNC1=O)Cl)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 27 mg/mL (185.51 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Gimeracil Research References

  1. [1] Itou J, Tsukihara H, Nukatsuka M, et al. 5-Chloro-2,4-dihydroxypyridine, CDHP, prevents lung metastasis of basal-like breast cancer cells by reducing nascent adhesion formation. Cancer Med (2018). PMID: 29356434 DOI: 10.1002/cam4.1265 Source material
  2. [2] Harada K, Ferdous T, Harada T, et al. Gimeracil enhances the antitumor effect of cisplatin in oral squamous cell carcinoma cells in vitro and in vivo. Oncol Lett (2017). PMID: 28927087 DOI: 10.3892/ol.2017.6602 Source material
  3. [3] Luukkonen PK, Sakuma I, Gaspar RC, et al. Inhibition of HSD17B13 protects against liver fibrosis by inhibition of pyrimidine catabolism in nonalcoholic steatohepatitis. Proc Natl Acad Sci U S A (2023). PMID: 36669104 DOI: 10.1073/pnas.2217543120 Source material

Added to your cart

View Cart Checkout
Loading...